lansoprazole has been researched along with Dysgeusia in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Dysgeusia: A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The most common adverse event was the dysgeusia in both the groups." | 2.87 | Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial. ( Shahbazi, S; Vahdat Shariatpanahi, Z, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shahbazi, S | 1 |
| Vahdat Shariatpanahi, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection[NCT02711176] | Phase 4 | 212 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lansoprazole and Dysgeusia
| Article | Year |
|---|---|
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infecti | 2018 |